Brought to you by 
Ablynx nets $214mm in Nasdaq IPO
03 Aug 2020
Executive Summary
Euronext Brussels-traded Ablynx NV (therapeutic protein platform known as Nanobodies) netted $214mm through an initial public offering on the Nasdaq exchange of 13.1mm ordinary shares (including the overallotment) in the form of American Depositary Shares (ADSs) with each ADS representing the right to receive one ordinary share at $17.50 apiece. The company originally planned to offer 9.2mm ADSs at a price between $17.90-19.08 per ADS.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ablynx nets $214mm in Nasdaq IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice